On June 3, 2019 Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, reported that the preliminary results of efficacy and safety of sintilimab, the anti-PD-1 antibody that co-developed with Eli Lilly and Company, in combination with CAPOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC) (NCT02937116, cohort F) were presented by poster at the 55th annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) [Abstract #4042; Monday, June 3, 8:00 AM -11:00 AM CDT] (Press release, Innovent Biologics, JUN 3, 2019, View Source [SID1234536845]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As the top and most influential international oncology conference, ASCO (Free ASCO Whitepaper) Annual Meeting provides the most important platform for publishing and discussing cutting edge clinical studies. Under the theme "Caring for Every Patient, Learning from Every Patient," 2019 ASCO (Free ASCO Whitepaper) Annual Meeting has attracted numerous top oncologists, scholars, staff from regulatory and patient organizations to share the latest updates and achievements in clinical oncology, with the ultimate goal to help deliver more promising medicines and treatment options to cancer patients.

It is worth noting that more and more Chinese companies choose to participate and disclose their programs in ASCO (Free ASCO Whitepaper), showcasing the importance of emerging Chinese biotech industry. As a leading Chinese biotech company, Innovent will provide key result update of several clinical studies at the ASCO (Free ASCO Whitepaper) 2019 Annual Meeting. The results on the treatment of relapsed or refractory extranodal NK/T cell lymphoma (ORIENT-4) with sintilimab will be presented in an oral session, and key data from several other clinical studies will be presented by posters and other sessions.

Gastric cancer is the second most common malignant tumor in China. The development of new agents for the treatment of advanced gastric cancer has been stagnant and unmet clinical need is high. NCT02937116 is an open-label, multicenter, Phase Ib study in China. Cohort F of the study contains 20 patients, designed to evaluate the efficacy and safety of sintilimab in combination with CAPOX for GC/GEJC in the first-line setting.

At the data cutoff (15 Jan 2019), the median follow up was 5.8 months (range, 2.4 to 12.5).

The objective response rate (ORR) was 85.0% (95% CI, 62.1 to 96.8).
The disease control rate (DCR) was 100.0% (95% CI, 83.2 to 100.0).
The median duration of response (DOR) was 5.3 months (95% CI, 4.8 to 7.2) and median progression free survival (PFS) was 7.5 months (6.2-9.4). Sintilimab showed an acceptable safety profile during the study.
"Over the past decade, the treatment of various malignant tumors has progressed rapidly. From traditional chemotherapy to targeted molecular therapy and immunotherapy, the prognosis of cancer patients has been improved remarkably. However, breakthroughs in the treatment of gastric cancer have been few. The efficacy data in Phase Ib study of sintilimab in gastric cancer is encouraging. We hope to see more positive data in the phase III study and provide more effective treatments for patients through our efforts," said Professor Nong Xu, Director of the Department of Oncology of the First Affiliated Hospital of Zhejiang University.

About Tyvyt (sintilimab injection)

Tyvyt (sintilimab injection) is an innovative drug jointly developed in China by Innovent and Eli Lilly and Company. Innovent is also conducting clinical studies of sintilimab injection in the United States. Tyvyt (sintilimab injection) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells. Tyvyt (sintilimab injection) is the only PD-1 antibody in China branded by both a local biopharmaceutical company and a global pharmaceutical company. Tyvyt (sintilimab injection) has been granted marketing approval by the National Medical Products Administration (NMPA) for relapsed or refractory classical Hodgkin’s lymphoma (r/r cHL) and has been included in the 2019 Guidelines of Chinese Society of Clinical Oncology (CSCO) for Lymphoid Malignancies. There are currently more than twenty clinical studies using sintilimab injection, including eight registration studies that evaluate the efficacy of sintilimab injection in other solid tumors.